Chromatin acetylation at transcription start sites and vitamin D receptor binding regions relates to effects of 1α,25-dihydroxyvitamin D3 and histone deacetylase inhibitors on gene expression

Nucleic Acids Research

Volumn 41, Issue 1, 2013, Pages 110-124

  Seuter, Sabine ^a   Heikkinen, Sami ^a   Carlberg, Carsten ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CHROMATIN MODIFIER TRICHOSTATIN A; HISTONE DEACETYLASE INHIBITOR; THROMBOMODULIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ACETYLATION; ARTICLE; BINDING SITE; CAMP GENE; CD93 GENE; CDKN2D GENE; CHROMATIN; CHROMATIN STRUCTURE; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DUSP10 GENE; EP300 GENE; GENE; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; GZF1 GENE; HBEGF GENE; HUMAN; HUMAN CELL; LOC200261 GENE; MICROARRAY ANALYSIS; NAPB GENE; NFKBIA GENE; NXT1 GENE; PRIORITY JOURNAL; RECEPTOR BINDING; SSTR4 GENE; THBD GENE; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UPREGULATION; VDR GENE;

ACETYLATION; BINDING SITES; CALCITRIOL; CELL LINE, TUMOR; CHROMATIN; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; RECEPTORS, CALCITRIOL; THROMBOMODULIN; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84871769796     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks959     Document Type: Article

References (68)

1. Eberharter, A. and Becker, P.B. (2002) Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep., 3, 224-229.
2. Perissi, V. and Rosenfeld, M.G. (2005) Controlling nuclear receptors: the circular logic of cofactor cycles. Nat. Rev. Mol. Cell Biol., 6, 542-554.
3. Carlberg, C. and Molnar, F. (2012) Current status of vitamin D signaling and its therapeutic applications. Curr. Top Med. Chem., 12, 528-547.
4. 3 receptor-corepressor partnership. FASEB J., 14, 1455-1463.
5. Abedin, S.A., Banwell, C.M., Colston, K.W., Carlberg, C. and Campbell, M.J. (2006) Epigenetic corruption of VDR signalling in malignancy. Anticancer Res., 26, 2557-2566.
6. Nottke, A., Colaiacovo, M.P. and Shi, Y. (2009) Developmental roles of the histone lysine demethylases. Development, 136, 879-889.
7. Greer, E.L. and Shi, Y. (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet., 13, 343-357.
8. Carlberg, C., Dunlop, T.W., Saramaki, A., Sinkkonen, L., Matilainen, M. and Vaisanen, S. (2007) Controlling the chromatin organization of vitamin D target genes by multiple vitamin D receptor binding sites. J. Steroid Biochem. Mol. Biol., 103, 338-343.
9. Lewis, B.A. and Reinberg, D. (2003) The mediator coactivator complex: functional and physical roles in transcriptional regulation. J. Cell Sci., 116, 3667-3675.
10. Marks, P.A., Richon, V.M., Breslow, R. and Rifkind, R.A. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol., 13, 477-483.
11. Monneret, C. (2005) Histone deacetylase inhibitors. Eur. J. Med. Chem., 40, 1-13.
12. 3. Nucleic Acids Res., 39, 502-512.
13. Pereira, F., Barbachano, A., Silva, J., Bonilla, F., Campbell, M.J., Munoz, A. and Larriba, M.J. (2011) KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum. Mol. Genet., 20, 4655-4665.
14. DeLuca, H.F. (2004) Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr., 80, 1689S-1696S.
15. Ingraham, B.A., Bragdon, B. and Nohe, A. (2008) Molecular basis of the potential of vitamin D to prevent cancer. Curr. Med. Res. Opin., 24, 139-149.
16. Verstuyf, A., Carmeliet, G., Bouillon, R. and Mathieu, C. (2010) Vitamin D: a pleiotropic hormone. Kidney Int., 78, 140-145.
17. Holick, M.F. (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr., 79, 362-371.
18. Lampen, A., Carlberg, C. and Nau, H. (2001) Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives. Eur. J. Pharmacol., 431, 25-33.
19. Khan, A.N. and Tomasi, T.B. (2008) Histone deacetylase regulation of immune gene expression in tumor cells. Immunol. Res., 40, 164-178.
20. Lee, M.J., Kim, Y.S., Kummar, S., Giaccone, G. and Trepel, J.B. (2008) Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol., 20, 639-649.
21. Shuttleworth, S.J., Bailey, S.G. and Townsend, P.A. (2010) Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr. Drug Targets, 11, 1430-1438.
22. Lin, R.J., Nagy, L., Inoue, S., Shao, W., Miller, W.H. and Evans, R.M. (1998) Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature, 391, 811-814.
23. Chang, T.H. and Szabo, E. (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin. Cancer Res., 8, 1206-1212.
24. 3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene, 20, 1860-1872.
25. Tavera-Mendoza, L.E., Quach, T.D., Dabbas, B., Hudon, J., Liao, X., Palijan, A., Gleason, J.L. and White, J.H. (2008) Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc. Natl Acad. Sci. USA, 105, 8250-8255.
26. 3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J. Steroid Biochem. Mol. Biol., 89-90, 245-249.
27. Klan, N., Seuter, S., Schnur, N., Jung, M. and Steinhilber, D. (2003) Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity. Biol. Chem., 384, 777-785.
28. 3. Nucleic Acids Res., 36, 121-132.
29. Thurn, K.T., Thomas, S., Moore, A. and Munster, P.N. (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol., 7, 263-283.
30. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 10, 142-153.
31. Warrener, R., Beamish, H., Burgess, A., Waterhouse, N.J., Giles, N., Fairlie, D. and Gabrielli, B. (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J., 17, 1550-1552.
32. Ramagopalan, S.V., Heger, A., Berlanga, A.J., Maugeri, N.J., Lincoln, M.R., Burrell, A., Handunnetthi, L., Handel, A.E., Disanto, G., Orton, S.M. et al. (2010) A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res., 20, 1352-1360.
33. Meyer, M.B., Goetsch, P.D. and Pike, J.W. (2012) VDR/RXR and TCF4/b-catenin cistromes in colonic cells of colorectal tumor origin: iImpact on c-FOS and c-MYC gene expression. Mol. Endocrinol., 26, 37-51.
34. 3 elicts a genome-wide shift in the locations of VDR chromatin accupancy. Nucleic Acids Res., 39, 9181-9193.
35. 3. J. Biol. Chem., 284, 8073-8082.
36. Metivier, R., Penot, G., Hubner, M.R., Reid, G., Brand, H., Kos, M. and Gannon, F. (2003) Estrogen receptor a directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell, 115, 751-763.
37. Carlberg, C. and Seuter, S. (2010) Dynamics of nuclear receptor target gene regulation. Chromosoma, 119, 479-484.
38. Carlberg, C. (2010) The impact of transcriptional cycling on gene regulation. Transcription, 1, 13-16.
39. Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T. and Tada, K. (1980) Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer, 26, 171-176.
40. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A. and Speleman, F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3, R34.
41. 3 is associated with cycling of corepressors and histone deacetylases. J. Mol. Biol., 400, 284-294.
42. Giresi, P.G. and Lieb, J.D. (2009) Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements). Methods, 48, 233-239.
43. Rashid, N.U., Giresi, P., Ibrahim, J.G., Sun, W. and Lieb, J.D. (2011) ZINBA integrates local covariates with DNA-seq data to identify broad and narrow regions of enrichment, even within amplified genomic regions. Genome Biol., 12, R67.
44. Giresi, P.G., Kim, J., McDaniell, R.M., Iyer, V.R. and Lieb, J.D. (2007) FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res., 17, 877-885.
45. ENCODE-Consortium. (2004) The ENCODE (ENCyclopedia Of DNA Elements) Project. Science, 306, 636-640.
46. Creyghton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W., Steine, E.J., Hanna, J., Lodato, M.A., Frampton, G.M., Sharp, P.A. et al. (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA, 107, 21931-21936.
47. Lozzio, C.B. and Lozzio, B.B. (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood, 45, 321-334.
48. Klein, E., Ben-Bassat, H., Neumann, H., Ralph, P., Zeuthen, J., Polliack, A. and Vanky, F. (1976) Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int. J. Cancer, 18, 421-431.
49. Greenlee, M.C., Sullivan, S.A. and Bohlson, S.S. (2012) CD93 and related family members: their role in innate immunity. Curr. Drug Targets, 9, 130-138.
50. 3 receptor signalling in prostate cancer cells. Oncogene, 23, 6712-6725.
51. Marks, P.A. (2007) Discovery and development of SAHA as an anticancer agent. Oncogene, 26, 1351-1356.
52. Michaelis, M., Doerr, H.W. and Cinatl, J. (2007) Valproic acid as anti-cancer drug. Curr. Pharm. Des., 13, 3378-3393.
53. Bialer, M. and Yagen, B. (2007) Valproic Acid: second generation. Neurotherapeutics, 4, 130-137.
54. Downs, J.A., Nussenzweig, M.C. and Nussenzweig, A. (2007) Chromatin dynamics and the preservation of genetic information. Nature, 447, 951-958.
55. Suzuki, H., Gabrielson, E., Chen, W., Anbazhagan, R., van Engeland, M., Weijenberg, M.P., Herman, J.G. and Baylin, S.B. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet., 31, 141-149.
56. Lee, H.S., Park, M.H., Yang, S.J., Jung, H.Y., Byun, S.S., Lee, D.S., Yoo, H.S., Yeom, Y.I. and Seo, S.B. (2004) Gene expression analysis in human gastric cancer cell line treated with trichostatin A and S-adenosyl-L- homocysteine using cDNA microarray. Biol. Pharm. Bull., 27, 1497-1503.
57. Chittur, S.V., Sangster-Guity, N. and McCormick, P.J. (2008) Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genom., 9, 507.
58. Dannenberg, L.O. and Edenberg, H.J. (2006) Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genom., 7, 181.
59. Roy, S., Jeffrey, R. and Tenniswood, M. (2008) Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Mol. Cancer Ther., 7, 1931-1939.
60. Banwell, C.M., MacCartney, D.P., Guy, M., Miles, A.E., Uskokovic, M.R., Mansi, J., Stewart, P.M., O'Neill, L.P., Turner, B.M., Colston, K.W. et al. (2006) Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin. Cancer Res., 12, 2004-2013.
61. Bantscheff, M., Hopf, C., Savitski, M.M., Dittmann, A., Grandi, P., Michon, A.M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G. et al. (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol., 29, 255-265.
62. Schauber, J., Oda, Y., Buchau, A.S., Yun, Q.C., Steinmeyer, A., Zugel, U., Bikle, D.D. and Gallo, R.L. (2008) Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1, 25-dihydroxyvitamin D3. J. Invest. Dermatol., 128, 816-824.
63. Wang, Z., Zang, C., Cui, K., Schones, D.E., Barski, A., Peng, W. and Zhao, K. (2009) Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell, 138, 1019-1031.
64. Cheng, C., Shou, C., Yip, K.Y. and Gerstein, M.B. (2011) Genome-wide analysis of chromatin features identifies histone modification sensitive and insensitive yeast transcription factors. Genome Biol., 12, R111.
65. Bannister, A.J. and Kouzarides, T. (2011) Regulation of chromatin by histone modifications. Cell Res., 21, 381-395.
66. Dawson, M.I. and Xia, Z. (2012) The retinoid X receptors and their ligands. Biochim. Biophys. Acta, 1821, 21-56.
67. Luo, W., Karpf, A.R., Deeb, K.K., Muindi, J.R., Morrison, C.D., Johnson, C.S. and Trump, D.L. (2010) Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res., 70, 5953-5962.
68. Schnur, N., Seuter, S., Katryniok, C., Radmark, O. and Steinhilber, D. (2007) The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes. Biochim. Biophys. Acta, 1771, 1271-1282.